A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer
A Phase 1b Study of OMP-305B83 Plus Weekly Paclitaxel in Subjects With Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
This is an open-label, Phase 1b dose escalation and expansion study of OMP-305B83 plus paclitaxel designed to evaluate the safety, efficacy and pharmacokinetics of OMP-305B83 in combination with paclitaxel in patients with platinum resistant ovarian, primary peritoneal or fallopian tube cancer. This study consists of a screening period, a treatment period and a post-treatment follow up period in which patients will be followed for survival for approximately 12 months. Patients will be enrolled in two stages: a dose-escalation stage and an expansion phase.
Approximately 30 patients will be enrolled in this study at approximately 5 study centers in the United States (U.S)..
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- University of Colorado, Anschutz Medical Campus
-
-
Florida
-
Tampa, Florida, Forente stater, 33612
- H. Lee Moffitt Cancer Center & Research Institute, Inc. (Moffitt Cancer Center)
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28204
- Levine Cancer Institute
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- Stephenson Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- The University of Pennsylvania Health System
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Tennessee Oncology, PLLC
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- The University of Texas, MD Anderson Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Platinum resistant Grade 2 or 3 ovarian, primary peritoneal or fallopian tube cancer
- Measureable disease per response evaluation criteria (RECIST) v1.1
- Prior bevacizumab
- Age > or = 21 years
- Adequate organ and marrow function
- For women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least 6 months after the termination visit.
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Treatment with any anti-cancer therapy, including radiotherapy, chemotherapy, biologic therapy. Prior therapy with weekly paclitaxel for recurrent disease, unless administered more than 2 years prior to enrollment, unless part of an upfront treatment strategy.
- History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, clinical signs or symptoms of gastrointestinaI obstruction or other known clinically signification gastrointestinal disease.
- Subjects with brain metastases
- Subjects with leptomeningial disease or neoplasms in the last 5 years
- Blood pressure >140/80
- Significant intercurrent illness that will limit the patient's ability to participate in the study
- Subjects with known metastases that are currently involving the lumen of the gastrointestinal tract.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, or anticipation of need for major surgical procedure during the course of the study
- Pregnant or nursing women
- New York Heart Association Classification II, III, or IV
- Inability to comply with study and follow up procedure
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: OMP-305B83 plus paclitaxel
|
administrert intravenøst
intravenous (in the vein) infusion
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of dose limiting toxicities (DLT)
Tidsramme: Subjects will be treated and observed for DLT through the end of the first cycle (Days 0-28).
|
The maximum tolerated dose (MTD) or maximum administered dose (MAD) will be determined in subjects treated with OMP-305B83 in combination with Paclitaxel
|
Subjects will be treated and observed for DLT through the end of the first cycle (Days 0-28).
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Progresjonsfri overlevelse
Tidsramme: Inntil 5 år
|
Inntil 5 år
|
|
Safety of OMP-30B583 in combination with Paclitaxel will be assessed by adverse event monitoring, physical exams, vital signs, clinical laboratory testing, ECGs, echocardiograms, anti-OMP-305B83 testing, and subject interview on an ongoing basis.
Tidsramme: Through study completion, an average of 6 months
|
Through study completion, an average of 6 months
|
|
To assess Immunogenicity (in terms of formation of anti-drug antibod(ies) against OMP-305B83 in percentage of subjects) of OMP-305B83 in combination with Paclitaxel
Tidsramme: Through study completion, an average of 6 months
|
Through study completion, an average of 6 months
|
|
Response Rate assessed by RECIST criteria 1.1
Tidsramme: At 56 day intervals while on treatment, through study completion, an average of 6 months
|
At 56 day intervals while on treatment, through study completion, an average of 6 months
|
|
Response Rate assessed by CA-125 criteria
Tidsramme: At 28 day intervals while on treatment, through study completion, an average of 6 months
|
At 28 day intervals while on treatment, through study completion, an average of 6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Genitale neoplasmer, kvinnelige
- Adnexal sykdommer
- Eggledersykdommer
- Egglederneoplasmer
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Antineoplastiske midler
- Immunologiske faktorer
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Antineoplastiske midler, fytogene
- Paklitaksel
- Antistoffer, bispesifikke
Andre studie-ID-numre
Andre studie-ID-numre
- B83-002
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .